Drug Profile
Research programme: small molecule therapeutics - Proximagen
Alternative Names: PAR-2 - Proximagen; SSAO inhibitor - Proximagen; TrkA - ProximagenLatest Information Update: 28 May 2018
Price :
$50
*
At a glance
- Originator Cambridge Biotechnology
- Developer Proximagen
- Class Small molecules
- Mechanism of Action AOC3 protein inhibitors; AOC3 protein modulators; PAR 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atopic dermatitis; Cancer; Inflammatory pain; Irritable bowel syndrome; Ulcerative colitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Atopic-dermatitis in United Kingdom
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in United Kingdom
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammatory-pain in United Kingdom